Sanofi-Aventis And Xuanwu Hospital Capital Medical University To Set Up Regeneration Lab
This article was originally published in PharmAsia News
Sanofi-Aventis will cooperate with Xuanwu Hospital Capital Medical University to set up a regeneration laboratory to focus on research of the central nervous system, metabolic disorders and geriatric diseases. Since 2007, the company has established strategic partnerships with China's leading academic institutions. These include Tianjin Institute of Hematology and Blood Diseases Hospital, which comes under the Chinese Academy of Medical Sciences; and Shanghai Institute for Biological Sciences. Sanofi-Aventis disclosed that it is likely to launch a new oncology drug by the end of the year. The company's China operation currently prioritizes R&D and it will continue to build close partnerships with academic institutions. (Click here for more - Chinese Language)
You may also be interested in...
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.